6 Months of the Healthonauts – What We´ ve Learned and Where We´ re Headed

In January 2024, Natalie Koster and Dr. Carsten von Blohn founded the Healthonauts, combining the best aspects of pharma consultancy and agency work, specifically targeting companies in the rare disease. Now, half a year into the foundation of the business, the founders Natalie Koster and Carsten von Blohn are taking stock:

Weiterlesen

Drawing up a multichannel action plan

There are numerous paid / earned / shared / owned channel to consider - as well as interconnections, HCP preferences, budget restrictions,... just to name a few.

Weiterlesen

Von Mensch zu Mensch – was wir von Pflegenden im Bereich der seltenen Erkrankungen lernen können

Was können Pharma- und Biotech-Unternehmen von Pflegenden lernen, die im direkten Austausch mit Menschen mit seltenen Erkrankungen stehen?

Weiterlesen

How to Develop a Drug in a Rare Disease?

When it comes to drug development in rare diseases, there are certain hurdles that must be taken compared to more prevalent diseases:

Weiterlesen

Spotting the zebras – strategies for patient finding in rare disease

Rare diseases are a group of indications with diverse symptoms and underlying etiologies, which have in common the very feature that names them – their rareness.

Weiterlesen

The Healthcare Shapers network

Proud to share that Healthonaut Natalie Koster has been accepted into the Healthcare Shapers network.

Weiterlesen

Rare Disease Launch

A recent analysis in Health Affairs found that 65% of orphan drugs* are approved for only one orphan indication.

Weiterlesen

The Healthonauts geht an den Start

Dr. Carsten von Blohn und Dr. Natalie Koster haben ein Beratungsunternehmen gegründet, in dem sie ihre Healthcare-Expertise aus Industrie und Agent...

Weiterlesen

Neugründung: The Healthonauts berät zu Rare Diseases

The Healthonauts ist ein Beratungsunternehmen, das sich auf Rare Diseases, Specialty Medicine und Biotech konzentriert.

Weiterlesen